Physician profile
Oren Mason
NPI 1104985332
$96,784.48
in general payments reported to CMS, 2019-2025
8 companies · $5,592 in 2025
The $5,592 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,292 · 2020: $5,203 · 2021: $30K · 2022: $3,117 · 2023: $24K · 2024: $20K · 2025: $5,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $35K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,995 · Travel and Lodging: $4,279 · Food and Beverage: $1,075 · Education: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,355.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,995.00 |
| Travel and Lodging | $4,278.68 |
| Food and Beverage | $1,074.93 |
| Education | $525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $30,004.32 | 2021-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $25,647.61 | 2019-2024 | Jornay Pm |
| Sumitomo Pharma America, INC. | $13,400.00 | 2023-2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $12,285.99 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $6,191.70 | 2024-2025 | |
| Eisai INC. | $5,202.78 | 2020 | |
| Arbor Pharmaceuticals, INC. | $3,989.50 | 2019 | |
| Collegium Pharmaceutical, INC. | $62.58 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oren Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.